Abstract
The natural history of symptomatic severe aortic stenosis (AS) heralds a poor prognosis—a paradigm that rightly drives valve intervention. A widely voiced corollary holds that once patients exceed their nation’s average life expectancy, aortic valve replacement offers no prognostic benefit. We argue that this corollary is statistically incoherent and potentially clinically harmful. Life expectancy at birth is a period average across a whole cohort, weighted by deaths at younger ages; it is not a ceiling on individual survival. Expectancy is conditional on survival already achieved: the longer a person has lived, the older they are expected to be at death. A man of 90 in England and Wales still has a mean of 3.9 years ahead of him, and an average 82-year-old will outlive an average 72-year-old. The patient who has 'beaten the average’ has, by surviving, demonstrated membership of a longer-lived stratum—precisely the group with most to gain from a durable valve. The hazard in AS is cardiac, not chronological: it tracks extravalvular cardiac damage, frailty and competing illness rather than the calendar, and stage, not age, discriminates outcome after valve replacement. Futility is real—advanced cardiac damage, established frailty and prognosis-dominating comorbidity do foreclose benefit—but age is an inaccurate proxy for it. Drawing on natural history and clinical trial data, including cardiac damage staging, national life tables and the deprivation gradient, we propose replacing age-based nihilism with conditional, comorbidity-adjusted prognostication, with the expected gain estimated, documented and stated explicitly as part of consent and shared decision-making.